This content is current only at the time of printing. This document was printed on 23 October 2021. A current copy is located at https://apvma.gov.au/news-and-publications/statements
Print this page
You are here
Statements
2021
- The APVMA’s response to the current mouse plague - 22 July 2021
- Senate Estimates May 2021 opening address – Ms Lisa Croft - 27 May 2021
- 22 March update: APVMA services restored - 22 March 2021
- 18 March update: APVMA service interruption - 18 March 2021
- 17 March update: APVMA service interruption - 17 March 2021
- APVMA service interruption - 16 March 2021
- Federal Court of Australia – Decision: Final regulatory decisions for certain swimming pool and spa sanitiser products - 17 February 2021
- Federal Court of Australia – Stay of decision: Final regulatory decisions for certain swimming pool and spa sanitiser products - 29 January 2021
2020
- Senate Estimates September 2020 opening address – Ms Lisa Croft - 22 October 2020
- Senate Estimates March 2020 opening address—Dr Chris Parker - 3 March 2020
2019
- Statement from the CEO - 12 December 2019
- APVMA response to 60 Minutes story on glyphosate - 9 September 2019
- Senate Estimates April 2019 opening address—Dr Chris Parker - 9 April 2019
- Senate Estimates February 2019 opening address—Dr Chris Parker - 19 February 2019
2018
- Senate inquiry November 2018 opening address—Dr Chris Parker - 20 November 2018
- Senate Estimates October 2018 opening address—Dr Chris Parker - 23 October 2018
- Response to Four Corners' story on Glyphosate - 8 October 2018
- Adjustments to the future business operating model - 2 July 2018
- Senate Estimates May 2018 opening address—Dr Chris Parker - 23 May 2018
- APVMA opening address—public hearing ANAO report on Pesticide and Veterinary Medicine Regulatory Reform—Dr. Chris Parker - 1 March 2018
- Senate Estimates opening address, Chief Executive Officer, Dr. Chris Parker - 27 February 2018
2017
- APVMA’s Armidale business operating model - 19 December 2017
- Senate Estimates opening address, APVMA interim CEO, Dr. Chris Parker - 24 October 2017